← Back to Search

Behavioral Intervention

Speech-Language Therapy for Primary Progressive Aphasia (CB3 Trial)

Phase 2

Recruiting

Led By Emily Roglaski, PhD

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18+ years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 assessment time points through study completion (up to 18 months)

Awards & highlights

No Placebo-Only Group

Summary

This trial will investigate the effects of two different treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The goal is to determine how speech-language therapy can improve communication abilities in individuals

Who is the study for?

This trial is for adults with mild to moderate Primary Progressive Aphasia (PPA), including conditions like Pick's Disease and Frontotemporal Dementia. Participants should be able to engage in speech-language therapy.

What is being tested?

The study compares two evidence-based speech-language therapies using a randomized controlled design, aiming to understand their impact on communication abilities in individuals with PPA.

What are the potential side effects?

Since the interventions are non-medical therapies focused on improving communication, no traditional side effects like those seen with medications are expected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 assessment time points through study completion (up to 18 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 assessment time points through study completion (up to 18 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 assessment time points through study completion (up to 18 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Communication Participation

Change in Communication Participation Person Centered Goals

Montgomery Burden Inventory (MBI)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Communication Bridge™Experimental Treatment1 Intervention

Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.

Group II: Evidence-Based Impairment FocusedActive Control1 Intervention

The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Communication Bridge™

2018

N/A

~200

0 / 1Eligibility criteria met